Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Michelle Frost phoenix-icrctsu@icr.ac.uk


Christophe Verstegen 0203 437 6886
phoenix-icrctsu@icr.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Back

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Recruiting

Open to: ALL

Age: 18.0 - N/A

London Manchester Sheffield Bournemouth London Cardiff

Medical Conditions

Breast Neoplasm
Triple Negative Breast Cancer (TNBC)
HRD

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation (cohorts A-D) or allocation according to HRD and germline BRCA1/2 mutation status (cohorts E-G). The trial consists of two parts: a post-neoadjuvant treatment preoperative WOP component (PART 1); and a post-operative component (PART 2).

Cohorts A-D: To assess whether short exposure to a DDR inhibitor or anti-PD-L1 immunotherapy in a preoperative WOP in patients with post-NACT high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.

Cohort E: To assess whether short exposure to a DDR inhibitor with or without anti-PD-1 immunotherapy in a preoperative WOP in patients with non-HRD associated TNBC and post-neoadjuvant treatment high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.

Cohorts F \& G: To assess whether short exposure to the DDR inhibitor olaparib with or without anti-PD-1 immunotherapy in a preoperative WOP in patients with HRD associated TNBC and post-neoadjuvant treatment high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2019 Dec 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.

PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.

AZD6738 was removed as intervention under investigation as of 06 August 2024 (due to formal closure of cohort B)

Intervention Arm Group : Cohort B (AZD6738 monotherapy);

Intervention Type : DRUG
Intervention Description : PART 1 (cohort C, and cohorts E-G): Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.

PART 2 (cohort C, and cohorts F and G): 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.

Cohort C was formally closed to recruitment since 06 August 2024.

Intervention Arm Group : Cohort C (olaparib monotherapy);Cohort E: non-HRD and gBRCA1gBRCA1/2 wildtype confirmed at HRD screening;Cohort F: gBRCA1/2 mutation confirmed at HRD screening;Cohort G: HRD & gBRCA1/2 wildtype confirmed at HRD screening;

Intervention Type : DRUG
Intervention Description : PART 1 (cohort D): Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.

PART 2 (cohorts A and D, and cohorts F and G): 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.

Cohorts A and D were formally closed to recruitment since 06 August 2024.

Intervention Arm Group : Cohort D (durvalumab monotherapy);Cohort F: gBRCA1/2 mutation confirmed at HRD screening;Cohort G: HRD & gBRCA1/2 wildtype confirmed at HRD screening;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Guy's and St Thomas' Hospital NHS Foundation Trust
    London
    SE1 9RT
  • Christie Hospital NHS Trust
    Manchester
    England
    M20 4BX
  • Weston Park Hospital
    Sheffield
  • Royal Bournemouth Hospital
    Bournemouth
    Dorset
    BH7 7DW
  • King's College Hospital
    London
    England
    SE5 9RS
  • Velindre Cancer Center at Velinde Hospital
    Cardiff
    Wales
    CF14 2TL

Christophe Verstegen 0203 437 6886
phoenix-icrctsu@icr.ac.uk


Michelle Frost phoenix-icrctsu@icr.ac.uk



The study is sponsored by Institute of Cancer Research, United Kingdom and is in collaboration with AstraZeneca.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03740893
Last updated 05 August 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top